EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
Article in PLOS ONE (March 2021)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Article in PLOS ONE (March 2021)
Article in Cancer Management and Research (June 2020)
Monograph (June 2019)